{
    "paper_id": "ab0bbf82d8c8dee2e8f25626cb5648ef4fe55a2b",
    "metadata": {
        "title": "Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and coronavirus",
        "authors": [
            {
                "first": "Paolo",
                "middle": [],
                "last": "Verdecchia",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Fabio",
                "middle": [],
                "last": "Angeli",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Gianpaolo",
                "middle": [],
                "last": "Reboldi",
                "suffix": "",
                "affiliation": {},
                "email": ""
            }
        ]
    },
    "abstract": [
        {
            "text": "E sler and Esler [1] recommend that angiotensin receptor blockers (ARBs) should not be discontinued until convincing data will confirm the hypothesis that the entry of SARS-CoV-2, which mainly occurs through binding to the pulmonary angiotensin-converting enzyme 2 (ACE2) receptors [2, 3] , is favored by the up-regulation of these receptors induced by ARBs. Several studies showed that upregulation of ACE2 receptors is induced not only by ARBs [4] [5] [6] [7] but also by ACE inhibitors [4] . The hypothesis that such up-regulation favors virus entry has never been proved. Correctly, Esler and Esler [1] point out that ACE2 up-regulation induced by ACE inhibitors and ARB has never been tested in the lungs, the predominant site of SARS-CoV-2 entry [2, 3] .",
            "cite_spans": [
                {
                    "start": 17,
                    "end": 20,
                    "text": "[1]",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 282,
                    "end": 285,
                    "text": "[2,",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 286,
                    "end": 288,
                    "text": "3]",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 446,
                    "end": 449,
                    "text": "[4]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 450,
                    "end": 453,
                    "text": "[5]",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 454,
                    "end": 457,
                    "text": "[6]",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 458,
                    "end": 461,
                    "text": "[7]",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 489,
                    "end": 492,
                    "text": "[4]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 752,
                    "end": 755,
                    "text": "[2,",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 756,
                    "end": 758,
                    "text": "3]",
                    "ref_id": "BIBREF2"
                }
            ],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "It is important to remark that available data from experimental and human studies are conflicting and some counter-intuitive findings suggest that ARBs may indeed be beneficial instead of harmful. Studies with SARS-Cov and MERS-Cov viruses showed that ACE2 receptors are 'downregulated' following their interaction with the virus [8, 9] . Of note, down-regulation of ACE2 was most prevalent in the pulmonary areas infected by virus but not in the surrounding areas [10] . ACE2 down-regulation induced by virus leads to a reduced formation of angiotensin 1-7 because of the reduced degradation of angiotensin II, with consequent accumulation of angiotensin II [9] . In animal models of pulmonary damage induced by sepsis, accumulation of angiotensin II induced inflammation, pulmonary edema and worsening of pulmonary function [11] . In these animal studies, pulmonary lesions were reduced not only by ARBs [9] but also by recombinant ACE2 [12] and angiotensin1-7 [13], suggesting that ACE2 activation contributes to limit pulmonary damage. In a recent study from China, a direct association has been found between circulating angiotensin II and the pulmonary damage in patients infected with SARS-Cov-2 virus [14] . Overall, these studies suggest that degradation of angiotensin II and production of angiotensin 1-7 through the action of ACE2 may effectively control pulmonary inflammation.",
            "cite_spans": [
                {
                    "start": 330,
                    "end": 333,
                    "text": "[8,",
                    "ref_id": "BIBREF8"
                },
                {
                    "start": 334,
                    "end": 336,
                    "text": "9]",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 465,
                    "end": 469,
                    "text": "[10]",
                    "ref_id": "BIBREF10"
                },
                {
                    "start": 659,
                    "end": 662,
                    "text": "[9]",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 826,
                    "end": 830,
                    "text": "[11]",
                    "ref_id": "BIBREF11"
                },
                {
                    "start": 1209,
                    "end": 1213,
                    "text": "[14]",
                    "ref_id": "BIBREF14"
                }
            ],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "So far, clinical evidence that ARBs may limit the pulmonary damage is scanty. A large study from the US compared, using propensity score matching, 11 498 patients with pneumonitis who were treated with ACE-inhibitors or ARBs with 11 498 patients with pneumonitis and not treated with these drugs [15] . Mortality at 30 days was 13% in the total population, 30% with ACE inhibitors and 4% with ARBs [15] . ARB treatment during hospital stay was associated with a lower mortality (odds ratio 0.47; 95% confidence interval 0.30-0.72) [15] . Further clinical studies in patients infected with SARS-2-Cov are eagerly awaited.",
            "cite_spans": [
                {
                    "start": 296,
                    "end": 300,
                    "text": "[15]",
                    "ref_id": "BIBREF15"
                },
                {
                    "start": 398,
                    "end": 402,
                    "text": "[15]",
                    "ref_id": "BIBREF15"
                },
                {
                    "start": 531,
                    "end": 535,
                    "text": "[15]",
                    "ref_id": "BIBREF15"
                }
            ],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "We agree that, at present, the suggestion to withdraw ACE inhibitors or ARBs in all patients who are receiving these drugs to prevent the diffusion of SARS-CoV-2 virus is neither based on sound clinical evidence nor is it supported by solid experimental studies. Conversely, and perhaps counter-intuitively, some data suggest that ARBs could be beneficial to limit pulmonary inflammatory lesions.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "ACKNOWLEDGEMENTS",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": "sler and Esler [1] recommend that angiotensin receptor blockers (ARBs) should not be discontinued until convincing data will confirm the hypothesis that the entry of SARS-CoV-2, which mainly occurs through binding to the pulmonary angiotensin-converting enzyme 2 (ACE2) receptors [2, 3] , is favored by the up-regulation of these receptors induced by ARBs. Several studies showed that upregulation of ACE2 receptors is induced not only by ARBs [4] [5] [6] [7] but also by ACE inhibitors [4] . The hypothesis that such up-regulation favors virus entry has never been proved. Correctly, Esler and Esler [1] point out that ACE2 up-regulation induced by ACE inhibitors and ARB has never been tested in the lungs, the predominant site of SARS-CoV-2 entry [2, 3] .",
            "cite_spans": [
                {
                    "start": 15,
                    "end": 18,
                    "text": "[1]",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 280,
                    "end": 283,
                    "text": "[2,",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 284,
                    "end": 286,
                    "text": "3]",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 444,
                    "end": 447,
                    "text": "[4]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 448,
                    "end": 451,
                    "text": "[5]",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 452,
                    "end": 455,
                    "text": "[6]",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 456,
                    "end": 459,
                    "text": "[7]",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 487,
                    "end": 490,
                    "text": "[4]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 601,
                    "end": 604,
                    "text": "[1]",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 750,
                    "end": 753,
                    "text": "[2,",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 754,
                    "end": 756,
                    "text": "3]",
                    "ref_id": "BIBREF2"
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "It is important to remark that available data from experimental and human studies are conflicting and some counter-intuitive findings suggest that ARBs may indeed be beneficial instead of harmful. Studies with SARS-Cov and MERS-Cov viruses showed that ACE2 receptors are 'downregulated' following their interaction with the virus [8, 9] . Of note, down-regulation of ACE2 was most prevalent in the pulmonary areas infected by virus but not in the surrounding areas [10] . ACE2 down-regulation induced by virus leads to a reduced formation of angiotensin 1-7 because of the reduced degradation of angiotensin II, with consequent accumulation of angiotensin II [9] . In animal models of pulmonary damage induced by sepsis, accumulation of angiotensin II induced inflammation, pulmonary edema and worsening of pulmonary function [11] . In these animal studies, pulmonary lesions were reduced not only by ARBs [9] but also by recombinant ACE2 [12] and angiotensin1-7 [13] , suggesting that ACE2 activation contributes to limit pulmonary damage. In a recent study from China, a direct association has been found between circulating angiotensin II and the pulmonary damage in patients infected with SARS-Cov-2 virus [14] . Overall, these studies suggest that degradation of angiotensin II and production of angiotensin 1-7 through the action of ACE2 may effectively control pulmonary inflammation.",
            "cite_spans": [
                {
                    "start": 330,
                    "end": 333,
                    "text": "[8,",
                    "ref_id": "BIBREF8"
                },
                {
                    "start": 334,
                    "end": 336,
                    "text": "9]",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 465,
                    "end": 469,
                    "text": "[10]",
                    "ref_id": "BIBREF10"
                },
                {
                    "start": 659,
                    "end": 662,
                    "text": "[9]",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 826,
                    "end": 830,
                    "text": "[11]",
                    "ref_id": "BIBREF11"
                },
                {
                    "start": 906,
                    "end": 909,
                    "text": "[9]",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 939,
                    "end": 943,
                    "text": "[12]",
                    "ref_id": "BIBREF12"
                },
                {
                    "start": 963,
                    "end": 967,
                    "text": "[13]",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 1210,
                    "end": 1214,
                    "text": "[14]",
                    "ref_id": "BIBREF14"
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "So far, clinical evidence that ARBs may limit the pulmonary damage is scanty. A large study from the US compared, using propensity score matching, 11 498 patients with pneumonitis who were treated with ACE-inhibitors or ARBs with 11 498 patients with pneumonitis and not treated with these drugs [15] . Mortality at 30 days was 13% in the total population, 30% with ACE inhibitors and 4% with ARBs [15] . ARB treatment during hospital stay was associated with a lower mortality (odds ratio 0.47; 95% confidence interval 0.30-0.72) [15] . Further clinical studies in patients infected with SARS-2-Cov are eagerly awaited.",
            "cite_spans": [
                {
                    "start": 296,
                    "end": 300,
                    "text": "[15]",
                    "ref_id": "BIBREF15"
                },
                {
                    "start": 398,
                    "end": 402,
                    "text": "[15]",
                    "ref_id": "BIBREF15"
                },
                {
                    "start": 531,
                    "end": 535,
                    "text": "[15]",
                    "ref_id": "BIBREF15"
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "We agree that, at present, the suggestion to withdraw ACE inhibitors or ARBs in all patients who are receiving these drugs to prevent the diffusion of SARS-CoV-2 virus is neither based on sound clinical evidence nor is it supported by solid experimental studies. Conversely, and perhaps counter-intuitively, some data suggest that ARBs could be beneficial to limit pulmonary inflammatory lesions.",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Esler",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Esler",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Hypertens",
            "volume": "38",
            "issn": "",
            "pages": "781--782",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Hoffmann",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Kleine-Weber",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Schroeder",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Kruger",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Herrler",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Erichsen",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Cell",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/j.cell.2020.02.052"
                ]
            }
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wan",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Shang",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Graham",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "S"
                    ],
                    "last": "Baric",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Virol",
            "volume": "94",
            "issn": "",
            "pages": "127--147",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "M"
                    ],
                    "last": "Ferrario",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Jessup",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "C"
                    ],
                    "last": "Chappell",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "B"
                    ],
                    "last": "Averill",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "B"
                    ],
                    "last": "Brosnihan",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "A"
                    ],
                    "last": "Tallant",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Circulation",
            "volume": "111",
            "issn": "",
            "pages": "2605--2610",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides",
            "authors": [
                {
                    "first": "P",
                    "middle": [
                        "E"
                    ],
                    "last": "Gallagher",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "M"
                    ],
                    "last": "Ferrario",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "A"
                    ],
                    "last": "Tallant",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Am J Physiol Cell Physiol",
            "volume": "295",
            "issn": "",
            "pages": "1169--1174",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Ishiyama",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "E"
                    ],
                    "last": "Gallagher",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "B"
                    ],
                    "last": "Averill",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "A"
                    ],
                    "last": "Tallant",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "B"
                    ],
                    "last": "Brosnihan",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "M"
                    ],
                    "last": "Ferrario",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Hypertension",
            "volume": "43",
            "issn": "",
            "pages": "970--976",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Jessup",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "E"
                    ],
                    "last": "Gallagher",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "B"
                    ],
                    "last": "Averill",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "B"
                    ],
                    "last": "Brosnihan",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "A"
                    ],
                    "last": "Tallant",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "C"
                    ],
                    "last": "Chappell",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "M"
                    ],
                    "last": "Ferrario",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63",
            "authors": [
                {
                    "first": "I",
                    "middle": [],
                    "last": "Glowacka",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Bertram",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Herzog",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Pfefferle",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Steffen",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "O"
                    ],
                    "last": "Muench",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "J Virol",
            "volume": "84",
            "issn": "",
            "pages": "1198--1205",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Kuba",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Imai",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Rao",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Gao",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Guo",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Guan",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Nat Med",
            "volume": "11",
            "issn": "",
            "pages": "875--879",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Matsuyama",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Nagata",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Shirato",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Kawase",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Takeda",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Taguchi",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "J Virol",
            "volume": "84",
            "issn": "",
            "pages": "12658--12664",
            "other_ids": {}
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "Angiotensinconverting enzyme 2 protects from severe acute lung failure",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Imai",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Kuba",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Rao",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Huan",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Guo",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Guan",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Nature",
            "volume": "436",
            "issn": "",
            "pages": "112--116",
            "other_ids": {}
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections",
            "authors": [
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Zou",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Yan",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Shu",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Gao",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Sun",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Nat Commun",
            "volume": "5",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "Angiotensin-(1-7) improves oxygenation, while reducing cellular infiltrate and fibrosis in experimental acute respiratory distress syndrome",
            "authors": [
                {
                    "first": "V",
                    "middle": [],
                    "last": "Zambelli",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Bellani",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Borsa",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Pozzi",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Grassi",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Scanziani",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Intensive Care Med Exp",
            "volume": "3",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Huang",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Yuan",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Sci China Life Sci",
            "volume": "63",
            "issn": "",
            "pages": "364--374",
            "other_ids": {}
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes",
            "authors": [
                {
                    "first": "E",
                    "middle": [
                        "M"
                    ],
                    "last": "Mortensen",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Nakashima",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Cornell",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "A"
                    ],
                    "last": "Copeland",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Pugh",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Anzueto",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "M"
                    ],
                    "last": "Mortensen",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Journal of Hypertension",
            "volume": "55",
            "issn": "",
            "pages": "0--000",
            "other_ids": {}
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "Varese and Department of Medicine and Cardiopulmonary Rehabilitation",
            "authors": [],
            "year": null,
            "venue": "J Hypertens",
            "volume": "38",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1097/HJH.0000000000002469"
                ]
            }
        }
    },
    "ref_entries": {},
    "back_matter": [
        {
            "text": "There are no conflicts of interest.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Conflicts of interest"
        }
    ]
}